Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:
Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the [...] Read more »
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
Freiburg, May 7th, 2025
Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat [...] Read more »
Dr. Falk Pharma gibt positive Ergebnisse seiner zulassungs-relevanten Phase-III-Studie zu Norucholsäure bei primär sklerosierender Cholangitis bekannt
Freiburg, den 7. Mai 2025
Die Studienergebnisse zeigen die Überlegenheit von Norucholsäure (NCA) gegenüber Placebo im kombinierten primären Endpunkt. Es gibt derzeit kein zugelassenes [...] Read more »
DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies
AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, le produit phare de DEBx Medical, a obtenu le prix IIWCG Achievement Award 2025 récompensant l’innovation dans le [...] Read more »
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the [...] Read more »
Curium schließt Übernahme von Monrol im Rahmen seines Plans zur erheblichen Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im Bereich der Positronen-Emissions-Tomographie (PET) ab
- Dies positioniert Curium als führenden Hersteller des Isotops Lu–177
- Integration innovativer [...] Read more »
Curium finalise l’acquisition de Monrol, axée sur le net renforcement de sa capacité de production de lutécium-177 et de son empreinte PET
- Affirmation de son leadership dans la production de l’isotope lutétium–177
- Renforcement de son expertise [...] Read more »
Curium Finaliza a Aquisição da Monrol como Parte do seu Plano para Expandir Significativamente a Capacidade de Lutécio-177 e Pegada PET
- Aquisição posiciona a Curium como principal fabricante do isótopo Lu–177
- Oferece experiência [...] Read more »
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint
- Positions Curium as leading manufacturer of Lu–177 isotope
- Brings innovative R&D expertise and pipeline to Curium
- Enhances Curium’s SPECT & PET geographical [...] Read more »
DEBx Medical Secures Expanded Investment from TVM Capital Healthcare
DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare.
AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 [...] Read more »